X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (266) 266
Newspaper Article (15) 15
Patent (11) 11
Book Review (4) 4
Book / eBook (2) 2
Book Chapter (1) 1
Conference Proceeding (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (133) 133
female (123) 123
oncology (104) 104
cancer (70) 70
ovarian neoplasms - genetics (62) 62
ovarian cancer (60) 60
middle aged (57) 57
adult (56) 56
mutation (55) 55
aged (50) 50
obstetrics & gynecology (50) 50
carcinoma (39) 39
genetic aspects (34) 34
women (34) 34
tumors (29) 29
analysis (28) 28
breast cancer (27) 27
chemotherapy (27) 27
brca1 (26) 26
ovarian neoplasms - pathology (25) 25
hematology, oncology and palliative medicine (24) 24
endocrine system diseases (23) 23
breast-cancer (22) 22
gene mutations (22) 22
obstetrics and gynecology (22) 22
ovarian neoplasms - drug therapy (22) 22
research (22) 22
survival (22) 22
aged, 80 and over (20) 20
brca1 protein - genetics (20) 20
genes (19) 19
genes, brca1 (19) 19
genes, brca2 (19) 19
homologous recombination (19) 19
ovarian-cancer (19) 19
poly polymerase (19) 19
brca2 (18) 18
breast (18) 18
care and treatment (17) 17
repair (17) 17
genomics (16) 16
ovarian carcinoma (16) 16
surgery (16) 16
dna (15) 15
fallopian-tube (15) 15
gene (15) 15
germ-line mutation (15) 15
male (15) 15
mutations (15) 15
multidisciplinary sciences (14) 14
prognosis (14) 14
skin and connective tissue diseases (14) 14
expression (13) 13
germline mutations (13) 13
ovarian neoplasms - metabolism (13) 13
platinum (13) 13
resistance (13) 13
abridged index medicus (12) 12
brca2 protein - genetics (12) 12
breast neoplasms - genetics (12) 12
cell line, tumor (12) 12
deoxyribonucleic acid--dna (12) 12
dna repair (12) 12
drug resistance, neoplasm - genetics (12) 12
immunohistochemistry (12) 12
animals (11) 11
diagnosis (11) 11
dna methylation (11) 11
fallopian tube neoplasms - genetics (11) 11
health aspects (11) 11
methylation (11) 11
beer (10) 10
biochemistry (10) 10
chemistry (10) 10
compositions thereof (10) 10
culture media (10) 10
enzymology (10) 10
genetic predisposition to disease (10) 10
genomes (10) 10
metallurgy (10) 10
microbiology (10) 10
microorganisms or enzymes (10) 10
mutation or genetic engineering (10) 10
neoplasm staging (10) 10
open-label (10) 10
organic chemistry (10) 10
peptides (10) 10
poly polymerase inhibitors - therapeutic use (10) 10
propagating, preserving or maintaining microorganisms (10) 10
risk (10) 10
spirits (10) 10
treatment outcome (10) 10
tumor suppressor protein p53 - genetics (10) 10
vinegar (10) 10
wine (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
brca1 protein (9) 9
cancer patients (9) 9
carcinoma - genetics (9) 9
cells (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Coleman, Robert L and Oza, Amit M and Lorusso, Domenica and Aghajanian, Carol and Oaknin, Ana and Dean, Andrew and Colombo, Nicoletta and Weberpals, Johanne I and Clamp, Andrew and Scambia, Giovanni and Leary, Alexandra and Holloway, Robert W and Gancedo, Margarita Amenedo and Fong, Peter C and Goh, Jeffrey C and O'Malley, David M and Armstrong, Deborah K and Garcia-Donas, Jesus and Swisher, Elizabeth M and Floquet, Anne and Konecny, Gottfried E and McNeish, Iain A and Scott, Clare L and Cameron, Terri and Maloney, Lara and Isaacson, Jeff and Goble, Sandra and Grace, Caroline and Harding, Thomas C and Raponi, Mitch and Sun, James and Lin, Kevin K and Giordano, Heidi and Ledermann, Jonathan A and Buck, M and Dean, A and Friedlander, M L and Goh, J C and Harnett, P and Kichenadasse, G and Scott, C L and Denys, H and Dirix, L and Vergote, I and Elit, L and Ghatage, P and Oza, A M and Plante, M and Provencher, D and Weberpals, J I and Welch, S and Floquet, A and Gladieff, L and Joly, F and Leary, A and Lortholary, A and Lotz, J and Medioni, J and Tredan, O and You, B and El-Balat, A and Hänle, C and Krabisch, P and Neunhöffer, T and Pölcher, M and Wimberger, P and Amit, A and Kovel, S and Leviov, M and Safra, T and Shapira-Frommer, R and Stemmer, S and Bologna, A and Colombo, N and Lorusso, D and Pignata, S and Sabbatini, R F and Scambia, G and Tamberi, S and Zamagni, C and Fong, P C and O'Donnell, A and Gancedo, M Amenedo and Herraez, A Casado and Garcia-Donas, J and Guerra, E M and Oaknin, A and Palacio, I and Romero, I and Sanchez, A and Banerjee, S N and Clamp, A and Drew, Y and Gabra, H G and Jackson, D and Ledermann, J A and McNeish, I A and Parkinson, C and Powell, M and Aghajanian, C and ... and ARIEL3 investigators and ARIEL3 Investigators
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 390, Issue 10106, pp. 1949 - 1961
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | BEVACIZUMAB | OPEN-LABEL | CANCER | HETEROZYGOSITY | EPITHELIAL OVARIAN | CHEMOTHERAPY | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Treatment Outcome | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Maintenance Chemotherapy - methods | Internationality | Ovarian Neoplasms - therapy | Female | Aged | Molecular Targeted Therapy - methods | Clinical trials | Care and treatment | Carcinoma | Drug therapy | Ovarian cancer | Cancer | Analysis | Chemotherapy | Ovarian carcinoma | Platinum | Biomarkers | Mutation | Cancer therapies | Evidence-based medicine | Tumors | Homologous recombination | Central nervous system | Poly(ADP-ribose) | Homology | Genomes | Fallopian tube | Anticancer properties | Metastases | Homologous recombination repair | Randomization | Pain | Motivation | Ribose | Hemoglobin | Alanine | Anemia | Poly(ADP-ribose) polymerase | Adenosine diphosphate | Breast cancer | Patients | Survival | Heterozygosity | Abdomen | Polymerase | Inhibitors | Point mutation | Loss of heterozygosity | Antitumor activity | Aspartate aminotransferase | Peritoneum
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
Nature communications, ISSN 2041-1723, 2018, Volume 9, Issue 1, pp. 3970 - 16
Journal Article
Journal Article
Cancer discovery, ISSN 2159-8290, 2017, Volume 7, Issue 9, pp. 984 - 998
Journal Article
Nature communications, ISSN 2041-1723, 2018, Volume 9, Issue 1, pp. 1849 - 14
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 25, pp. 2403 - 2415
The addition of veliparib, a PARP inhibitor, to induction chemotherapy and maintenance therapy in women with advanced ovarian cancer significantly improved... 
OLAPARIB | MEDICINE, GENERAL & INTERNAL | PRIMARY SURGERY | PRIMARY PERITONEAL CANCER | DOUBLE-BLIND | PLATINUM | FALLOPIAN-TUBE | OPEN-LABEL | PHASE-2 | EPITHELIAL OVARIAN | PARP INHIBITOR VELIPARIB | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - drug therapy | Ovarian Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Adult | Female | Maintenance Chemotherapy | Genes, BRCA1 | Benzimidazoles - adverse effects | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Benzimidazoles - therapeutic use | Double-Blind Method | Administration, Oral | Carboplatin - administration & dosage | Combined Modality Therapy | Poly(ADP-ribose) Polymerase Inhibitors - adverse effects | Cystadenocarcinoma, Serous - surgery | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Intention to Treat Analysis | Quality of Life | Aged | Mutation | Ovarian Neoplasms - surgery | Chemotherapy, Combination | Enzyme inhibitors | Drug therapy | Patient outcomes | Ovarian cancer | Testing | Thrombocytopenia | Adenosine | Statistical analysis | Ovarian carcinoma | Homologous recombination | Nausea | Breast cancer | Cancer therapies | Survival | Patients | Chemotherapy | Motivation | Ribose | Surgery | Paclitaxel | Carboplatin | Population | Tumors
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2017, Volume 35, Issue 19, pp. 2193 - 2202
Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular endothelial growth factor signaling by vascular... 
SENSITIVE OVARIAN-CANCER | MULTICENTER | ANTI-PD-1 | ONCOLOGY | ANTITUMOR-ACTIVITY | NIVOLUMAB | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Journal Article